Navigation Links
Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer
Date:7/28/2009

CINCINNATI, July 27 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today appointed Stephen Cutler, PhD, as the Company's new Senior Vice President and Chief Operating Officer (COO) effective immediately. Dr. Cutler brings to Kendle more than 20 years of senior management and operations leadership experience in the CRO and biopharmaceutical industries to position the Company for continued growth as a top-tier global CRO. Dr. Cutler will provide global leadership for the Company's worldwide Late Stage operations, leveraging its combined capabilities across Phase II-IV to maximize delivery of integrated service offerings for customers. He assumes the COO role from Chris Bergen who has been appointed Executive Vice President and Chief Administrative Officer (CAO). Dr. Cutler will report directly to Chairman and CEO Candace Kendle, PharmD.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )

"I am pleased to join Kendle and look forward to being part of its future growth and success," said Dr. Cutler. "The long-term outlook for clinical development outsourcing remains strong, and I am committed to furthering Kendle's focus on operational excellence and strategic customer relationships across the Phase II-IV market to drive increased value for our customers and shareholders moving forward."

Dr. Cutler joins Kendle following 14 years with Quintiles where he most recently was Senior Vice President, Global Project Management responsible for the global project management group, including more than 600 people and 500 active projects spanning all therapeutic areas. Previously, he was Senior Vice President, Clinical, Medical and Regulatory, leading more than 1,200 associates based in North America with responsibility for approximately 200 projects. Dr. Cutler's experience with Quintiles also includes serving as Senior Vice President, Project Management - Europe responsible for all international full-service projects and Vice President, Oncology - Europe as well as regional leadership positions in South Africa and Australia. While at Quintiles Dr. Cutler served on the company's senior clinical development management and corporate strategic planning teams and served in executive sponsor roles for key customer relationships.

Prior to joining Quintiles Dr. Cutler was with Sandoz (now Novartis) for eight years in Australia and Europe where he served as a Group Head providing leadership for Phase I-III trials in a broad spectrum of therapeutic areas. He holds a Doctorate in Philosophy from the University of Sydney in Sydney, Australia, and a Master's of Business Administration from the University of Birmingham in Birmingham, England.

The addition of Dr. Cutler as Kendle's Senior Vice President and COO complements other recent moves by the Company to strengthen its executive leadership team. The Company today announced the appointment of Mr. Bergen as Executive Vice President and CAO to provide dedicated executive leadership for strategic technology and infrastructure enhancement initiatives with a focus on driving increased innovation, productivity and global connectivity.

In addition, reflecting Kendle's increasing focus on strategic customer relationships, Simon Higginbotham is adding the Chief Marketing Officer (CMO) role to his leadership of the Company's Early Stage business, assuming the title of Senior Vice President and CMO effective immediately.

Additional moves to enhance key strategic roles within the Company's C-suite in recent months include the appointments of Jarrod Pontius as Vice President, Chief Legal Officer and Secretary and the appointment of Keith Cheesman as Senior Vice President and Chief Financial Officer.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Names Jarrod Pontius Chief Legal Officer
2. Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila
3. Kendle Announces First Quarter 2009 Results
4. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
5. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
6. Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine Notable People in R&D
7. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
8. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call
9. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
10. Kendle to Present at the 2008 Credit Suisse Health Care Conference
11. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... DIEGO , Feb. 16, 2017  Dermata ... innovative products to treat a variety of dermatological ... million Series 1a financing and entered into a ... (SVB).  Dermata intends to use the capital for ... making major advancements in the treatment of serious ...
(Date:2/16/2017)... ... 2017 , ... AxioMed announced today the success of the ... completed the procedure on Monday, Jan. 30 at Andrews Memorial Hospital in Kingston, ... degenerative disc disease with radiculomyelopathy, as a result of degenerative cervical discs at ...
(Date:2/16/2017)... BOSTON , Feb. 16, 2017 /PRNewswire/ ... for rare genetic deficiencies that result in ... of a $41 million mezzanine round of ... Ipsen, OrbiMed, MPM Capital, New Enterprise Associates, ... an undisclosed public healthcare investment fund. Rhythm ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... further extended its industry leading Biochemistry Services specifically targeting the rapidly growing ... and methods for the biochemical and biosimilar characterization , product-related impurity ...
Breaking Biology Technology:
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice Recognition ... to match it against a stored voiceprint template. ... pitch, cadence, and tone are compared to distinguish ... hardware installation, as most PCs already have a ... transactions. Voice recognition biometrics are most likely to ...
Breaking Biology News(10 mins):